The First 90 Days: Where Operational Readiness Breaks Down — and How Strong Teams Respond  

March 2026

Most life sciences teams begin the year with solid plans– budgets are approved, priorities are clear, and resourcing models look reasonable– and then Q1 happens. By the first 90 days, operational readiness starts being tested by real work, constraints, and pressure.  

That’s when gaps surface — not because teams failed to plan, but because execution reveals what planning can’t fully predict. 

We’ve worked closely with life sciences organizations across quality, operations, and leadership teams. What we consistently see is that the first quarter doesn’t create problems — it exposes them. 

Why the First 90 Days Matter More Than Teams Expect 

The first 90 days of the year is usually the time when workloads are ramping up, regulatory pressure is increasing, and new initiatives are launched and underway.  

Internal teams shift from alignment meetings to delivery mode, and those small inefficiencies that were manageable in January become persistent distractions by March. 

The teams that perform best don’t avoid pressure. They recognize potential bottlenecks early and respond while change is still manageable. 

Where Operational Readiness Commonly Breaks Down 

While every organization is different, the breakdowns we see in the first 90 days tend to fall into a few consistent areas. 

1. Execution Outpaces Capacity 

Plans may account for volume, but they often underestimate how quickly priorities will shift. 

Without access to flexible expertise, critical roles become bottlenecks; specialized expertise is stretched thin; and teams rely on overtime or short-term workarounds to keep up. Over time, this slows progress, drains teams, and increases risk — even if deliverables are technically met.  

Strong teams plan not just for workload, but for on-demand flexibility when priorities shift and demand hits. 

2. Visibility Lags Behind Reality 

In Q1, leaders often realize they’re reacting to issues rather than anticipating them. 

Operations start to reveal drifting investigation timelines, gaps in supplier readiness, and dependencies between functions— often later than ideal. 

The problem isn’t a lack of data. Most teams have the key information they need to inform decisions, but that information arrives after decisions need to be made. 

Teams with early visibility can course-correct calmly and in a timely manner. Teams without it spend time escalating and reprioritizing. 

3. Supplier and Third-Party Risk Surfaces Quietly 

External partners rarely fail loudly at the start of the year. 

Instead, small gaps appear: delayed documentation, inconsistent practices, and slow responses to change. These issues don’t feel urgent at first, but they accumulate — especially under regulatory or delivery pressure. 

Organizations that verify supplier readiness early avoid far more costly intervention later. 

4. Systems Hold — or They Don’t 

Q1 reveals whether systems are supporting work and can withstand pressure or if teams are propping them up. 

When processes require constant escalation, manual intervention, or exception handling, pressure compounds quickly. Documentation may technically exist, but it doesn’t always reflect how work is being done. 

Teams that trust their systems spend less time firefighting and more time improving performance. 

5. Functional Alignment Erodes Under Pressure 

Most organizations start the year aligned. 

By March, competing priorities, unclear ownership, and inconsistent escalation paths can begin to fray that alignment. Decisions slow down. Meetings increase. Friction replaces momentum. 

This isn’t a leadership failure — it’s an execution reality. Strong teams address alignment intentionally before it becomes a drag on performance. 

How Strong Teams Respond in the First 90 Days 

The organizations that navigate Q1 successfully don’t wait for problems to become urgent. They act early and deliberately. 

They: 

• Treat small issues as signals 

• Reassess capacity and expertise before teams burn out 

• Strengthen visibility into where timelines and risk are drifting 

• Validate supplier readiness instead of assuming it 

• Course-correct while changes are still manageable 

Most importantly, they resist the temptation to “push harder” and instead focus on stabilizing execution. 

The Opportunity in the First 90 Days 

The first quarter is often the easiest time to intervene– issues are contained, adjustments don’t yet require major disruption, and teams are open to change because pressure is visible and not yet overwhelming.  

By the time similar issues surface later in the year, the stakes are higher. 

Organizations that leverage the first 90 days to reinforce readiness tend to experience fewer surprises, more predictable execution, stronger regulatory confidence, and better use of people and skills.  

Taking the Next Step 

The first 90 days often provide valuable signals about where readiness is holding — and where it may need reinforcement. 

For teams that want a simple way to pressure-test those signals internally, we’ve put together a short 2026 Operational Readiness Checklist that reflects the patterns we see most often early in the year. 

It’s designed to be reviewed quickly and used as a conversation starter — not a scorecard.

If it’s helpful, you can download the checklist here: 
→ 2026 Operational Readiness Checklist 

If it’s helpful to talk through where your organization may be feeling strain early this year, we’re always happy to connect. 

How OQSIE Supports Teams in the First 90 Days 

At OQSIE, we work with life sciences organizations during exactly this window — helping teams stabilize execution, close early gaps, and strengthen readiness before issues escalate.  

Whether it’s bridging capacity with experienced consultants, strengthening quality systems, or improving visibility through predictive insight, our focus is on practical support that holds up under real-world pressure. 

2026 Operational Readiness: What High-Performing Life Sciences Teams Are Doing Now

How to prepare your quality, operations, and leadership teams for a more complex regulatory and operational landscape. 

December 2025

As 2025 comes to a close, life sciences leaders are taking a hard look at their operational foundations. Between shifting FDA expectations, resource shortages, and rising complexity, teams that are preparing early will see the biggest operational wins in 2026.  

To help you assess where you stand — and where to focus — we’ve highlighted some key areas to show what operational readiness looks like in 2026:

1. Quality Systems Must be Strong Enough to Withstand Pressure 

Audit readiness has evolved from gathering essential documents to ensuring sites have repeatable processes, clear ownership, and evidence of effective remediation. It is imperative to success to have a level of quality system maturity that holds up when things get complicated.  

In practice, this looks like: 

• Investigations closed within standard timelines, with extensions as rare exceptions 

• Documentation that isn’t just standardized– but consistently lived day-to-day 

• Proactive trending of deviations, not just retrospective clean-up 

• Strong effectiveness checks on CAPAs 

• Audit readiness extending beyond internal teams to critical suppliers 

These foundations don’t just help companies pass inspections– they help avoid the operational pitfalls of rework, firefighting, and daunting backlog.  

2. Capacity Planning Has Become a Strategic Advantage  

This year, teams were stretched thin and expected to do more with less. The organizations that delivered on their 2025 commitments weren’t necessarily larger– they were more flexible.  

High-performing teams approached capacity proactively by:  

• Forecasting workload early 

• Mapping capability gaps across functions (QA, QC, Ops, Regulatory, etc.) 

• Bringing in specialized consultants to bridge temporary surges 

• Filling niche skill needs without over-hiring 

In one engagement, a client’s daunting warning letter activities were quickly acted upon with a targeted deployment of OQSIE consultants– allowing our client to complete commitments ahead of schedule. That kind of agility will define success in 2026.  

3. Predictive Analytics is Moving from “Nice to Have” to Core Infrastructure 

For years, AI in life sciences has been centered on potential. In 2025, more companies started experimenting with advanced solutions. Those teams that have embedded predictive tools have gained deeper visibility and will gain higher performance rewards in 2026.   

The foundations matter. The organizations that saw meaningful impact weren’t the ones with the most sophisticated models — they were the ones that had: 

• Clean, trustworthy data 

• Clear business problems to solve (investigation cycle time, downtime, capacity forecasting, etc.) 

• Leadership support for change 

• Collaboration across functions 

• Willingness to pilot, iterate, and refine 

The result? Faster decision-making, less surprises, and fewer last-minute escalations. In an industry defined by compliance and timing, predictive insight is becoming more than just a competitive advantage. 

4. Supplier and Third-Party Oversight Can’t Lag Behind  

With more life sciences organizations depending on contract manufacturers and third-party partners, 2025 exposed a critical truth: your suppliers must be as audit-ready as your internal teams — because their failure becomes your risk. 

Teams that got this right: 

• Conducted early supplier assessments 

• Ensured documentation quality matched internal expectations 

• Implemented monitoring and trending for supplier deviations and changes 

• Performed readiness checks well before FDA interactions 

• Built regular communications between internal teams and external sites 

OQSIE saw this firsthand when we helped a U.S. client prepare a third-party manufacturer in China for a PAI audit. After a structured gap analysis and targeted remediation, the site passed with flying colors — and passed a follow-up audit two years later with zero observations. 

5. Cross-Functional Alignment is the Glue That Holds Everything Together  

Even the best systems and tools fail without consistent alignment. This year, the strongest teams were the ones that broke down silos between QA, QC, Regulatory, Supply Chain, and Operations. They had shared priorities, dashboards, and ownership of outcomes. 

These teams thrived because: 

• Everyone had the same view of risks and timelines 

• Communication was consistent — not crisis-driven 

• Escalations were predictable 

• Leadership signaled clear support across functions 

As 2026 approaches, cross-functional alignment isn’t simply “nice to have.” It’s the mechanism that keeps companies steady when inspections appear and timelines compress. 

So, what does 2026 operational readiness look like? 

It is starting the year with: 

1. A QMS that works under pressure 

2. The talent and expertise to execute without bottlenecks 

3. The operational maturity to benefit from predictive tools 

4. Suppliers who won’t introduce hidden risk 

5. Teams aligned around shared priorities and clear governance 

Organizations that invest in these pillars will be able to operate with confidence, consistency, and control. 

And if you’re not sure where to start? That’s exactly what we’re here for. 

OQSIE helps life sciences companies strengthen systems, build capacity, implement predictive tools, and prepare both internal teams and suppliers for regulatory success. Let’s talk about your 2026 plans and how we can help execute them.  

How Life Science Leaders Can Avoid Costly Delays with Predictive Analytics

From missed deadlines to measurable success – how one company cut investigation closure time nearly in half.

September 2025

In the life sciences industry, delays in quality management systems don’t just create frustration — they can stall product launches, invite FDA audit observations, and drain resources. For leaders under constant pressure to deliver, avoiding costly delays can mean the difference between success and failure. 

One of the most common sources of these costly setbacks? Quality Deviations and Investigations  

Turning Chaos Into Clarity: Predictive Analytics on Quality Investigations

When it comes to quality investigations, extensions and delays can quickly turn into a common occurrence. Timelines often stretch longer than expected, due dates are repeatedly extended, and shifting priorities consume valuable hours.  

These delays are not just a quality issue; they impact the bottom line and can lead to serious consequences including:  

• Delayed time-to-market  

• Regulatory risk  

• Low morale and high turnover  

This is where implementing predictive analytics can make a huge difference. One recent client engagement illustrates just how powerful this approach can be. 

Case Study: Tackling Investigation Variability with Predictive Analytics

A client came to us struggling with significant variability in their investigation closure timelines. Their team was facing:  

• Frequent extensions on due dates 

• Constant priority changes 

• Very long hours, low morale, and high turnover within the QA group 

The investigation process wasn’t just slowing operations — it was eroding team performance and jeopardizing compliance. 

OQSIE’s Approach to Implementing Predictive Analytics:

Our team broke down the investigation process into five steps. From there, we: 

• Identified sources of variability in each step. 

• Developed a predictive model to forecast closure timelines based on process progression. 

• Implemented an alert and escalation system to flag issues tied to predicted close dates. 

• Accounted for variability drivers such as: 
  • Investigator work cadence 
  • Investigator workload 
  • CAPA agreement cycle time 
  • Prior investigations of the product 
  • Characteristics of the investigation (e.g., elapsed time from event, functional group launching it, manufacturing process involved) 

Measurable Results:

By bringing predictability to the process, our client not only accelerated timelines but also rebuilt confidence and morale across their team. The results were transformative: 

• Average closure time dropped from 65 to 35 days. 

• Investigations requiring extensions fell from 80% to just 25%. 

• Priority meetings were reduced from twice daily to once weekly. 

• Overtime and turnover in the QA group declined by 90%. 

This wasn’t just a process improvement. It was a shift from firefighting to predictable, proactive quality management. 

The Bottom Line

Costly delays don’t have to define your operations. This success story shows what’s possible when current quality system procedures are optimized with predictive tools. Life science leaders eliminate variability, reduce risk, and create a pathway to operational excellence. 

With OQSIE as your guide, you can build systems that create reliability, efficiency, and trust.  

Don’t let delays hold your organization back. Submit a project request today to learn how OQSIE can help you unlock measurable results with predictive analytics. 

Preparing For AI-Driven FDA Regulatory Reviews

June 2025

The FDA’s recent launch of its Artificial Intellgence (AI) tool, Elsa, marks a historic shift in how life sciences companies will be evaluated. With AI helping regulators identify high-priority inspection targets, your quality management system (QMS) may either be your greatest asset—or your biggest liability. 

This is just the start of the FDA’s AI journey. They expect the tool to mature and have plans to integrate more AI into different processes across the organization.  

So, what does this mean for life sciences companies and what steps should your organization be taking to keep up with the pace of innovation?  

AI Is Raising the Bar for Quality  

The use of AI opens the door for regulators to detect systemic issues, patterns of deviation handling, inconsistencies in CAPA closure, and more—at scale.  

As the FDA continues expanding their AI capabilities, it is essential for quality teams to optimize their procedures and establish processes that detect and prevent issues from occurring.  

The Risk of an Outdated QMS 

If your QMS is still heavily manual, fragmented across departments, or lacks real-time documentation capabilities, you’re behind. AI-powered inspections will spotlight weak links in your processes that might previously have gone unnoticed. 

Audit-readiness has never been so crucial, and to ensure your QMS is not at risk, consider assessing common vulnerabilities and areas for improvement. 

Common vulnerabilities include: 

• Incomplete audit trails 

• Delayed or inconsistent deviation investigations 

• Poorly linked quality events and CAPAs 

• Non-standard data entry formats 

• Paper-based records, manual data entry leads to inconsistencies 

• Reactive compliance strategies 

• Missing or inadequate procedures 

What was once “good enough” might soon fall short of regulatory expectations. 

Future-Proof Your Quality Systems with OQSIE 

Now is the time to assess whether your systems are built for an AI-informed regulatory environment and start establishing procedures that promote continuous improvement. Here are three recommended steps you can take: 

1. Audit Your System: Assess gaps and identify steps for improvement in your current QMS. 

2. Modernize Your Infrastructure: Implement digital-first tools to streamline data traceability and accessibility.

3. Strengthen Your Processes: Leverage AI and other advanced technology to streamline procedures and create a culture of continuous improvement with real-time and predictive data.  

Regulators are turning to AI to keep up with the rapid innovation and complexity of the life sciences industry, and if your systems aren’t up to the same standard, you risk falling behind. 

An AI-ready QMS doesn’t just protect you from noncompliance—it accelerates your path to market, boosts operational efficiency, and prepares you for whatever the future holds. 

OQSIE has helped some of the most respected life sciences organizations enhance their quality systems. Let us help you stay ahead of the curve. Contact us to schedule a QMS Strategy Session.  

FDA Compliance: Keys to a Robust Regulatory Strategy

March 2025

In the life sciences industry, mistakes are inevitable. Even the most established companies face FDA citations, deviations, and quality issues. The key difference between the companies that persevere and those that struggle is not about the mistakes made, but how they respond, correct, and prevent recurrence.  

The FDA’s Real Focus 

When you look at the most common reasons why pharmaceutical and medical device companies have received citations over the past 15 years, the prevailing theme is issues with procedures. Most companies are cited for either not having proper procedures to deal with quality issues, or not properly following the procedures they do have in place.  

Regulatory bodies do not expect a flawless system, but they do expect the ability to identify root causes, take proper corrective actions, and cultivate continuous improvement.  

Most Common Topics Found in 483 Citations 

A poorly structured and/or executed regulatory strategy can lead to costly remediations, reputational damages, and worst-case, operational interruptions. While the FDA inspects many aspects of a quality system, there are some key areas companies can focus on to ensure they have a well-managed strategy and execution: 

1. Clear Root Cause Analysis on Investigations: Did you properly investigate and understand why an issue occurred? 

2. Corrective & Preventive Actions (CAPA): Have you taken steps to fix the problem and prevent it from happening again? 

3. Procedures & Documentation: Can you provide clear records of your procedures and documented evidence that you’re following them? 

The FDA isn’t focused on perfection—they want to see how you fix and prevent problems. They are looking for continuous improvement and if your team prioritizes compliance and quality, or if you just react to quality system failures. 

Gaining a Competitive Advantage  

Today’s regulatory landscape is evolving faster than ever, and companies who treat quality and compliance as a strategic opportunity rather than an obstacle are gaining an edge over competitors.  

A strategic and proactive approach goes well beyond maintaining compliance, it reduces operational costs and opens opportunities for improving the bottom line and actively contributing to an organization’s success. This looks like real-time documentation, preventive detection, and constant visibility into the performance of quality systems.  

At OQSIE, we partner with life science leaders to build resilient quality systems that go beyond meeting compliance—they drive business success. Is your organization prepared for its next FDA audit and ready to take compliance to the next level? Let’s discuss how we can help. 

Key Industry Trends To Watch Out for in 2025

December 2024

As the life sciences industry continues to advance, there are some trends gaining momentum that operational leaders should prepare for as 2024 comes to a close.

Here are three trends to watch out for in the life sciences industry in 2025:

1. Increase Use of Artificial Intelligence (AI) in Operations

AI has been a trending topic for some time now, and while most organizations have been focused on applying this technology in the research and development (R&D) space, few are just scratching the surface in operations.

When it comes to Generative AI, McKinsey’s research suggests that the potential opportunity for the pharmaceutical operations value chain is $4 billion to $7 billion.¹ This technology is expected to reduce supply chain and quality costs and increase overall productivity across all operational functions.

In the next year, AI will continue to make strides across functional areas and will especially gain momentum in supply chain and manufacturing organizations. A recent report by Arnold & Porter found that 62% of life sciences senior executives are actively using or plan on using AI in manufacturing.²

LogiPharma’s recent report, where they surveyed 100 European supply chain leaders, also found that 40% of companies are prioritizing AI for demand forecasting and minimizing waste.³

Those companies who are currently leveraging AI and experiencing the benefits in other areas will carry that momentum into their manufacturing, supply chain, and quality organizations over the next year.

2. Evolving Regulatory Environment 

As the industry continues to evolve with real-time data, personalized medicines, and other advancements, so will the regulatory environment.

To keep up with the industry progression, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have been working on adaptive regulatory pathways for advanced therapies and scientific innovations.⁴

The industry is also expecting global regulatory harmonization efforts to continue as more agencies across the world increasingly adopt the International Council for Harmonisation’s (ICH) guidelines.⁴

You can read more about these emerging regulatory trends here.

3. High Demand for Digital Skills

It should come to no surprise that the demand for digital skills will keep increasing across entire organizations as more companies continue digitizing and implementing advanced technology.

Deloitte’s data shows that the demand for digital roles in the life sciences industry has significantly increased over the last five years. Since 2019, job postings for data engineers have increased by 69% and 16% for data scientists.⁵

When it comes to supply chain, 83% of leaders acknowledge the need to upskill or reskill a significant portion of their supply chain workforce to support digital transformation, according to Deloitte’s survey.⁵

Their survey also found that the top three roles most needed are data scientists and engineers, functional experts, and AI specialists.⁵ 

Operational leaders can expect heightened competition in the next year to access professionals with both functional and digital skills to support their transformation initiatives.  

The industry is advancing rapidly and to stay competitive, leaders must prepare their organizations to embrace advanced technology, create strategic partnerships to stay on top of ever-changing regulations, and prioritize talent development and the acquisition of niche digital skills.

Those who focus on leveraging these trends can position their organizations to lead in efficiency and performance within a competitive and dynamic landscape.  

Want to ensure your organization is prepared to overcome challenges in 2025? Submit a request for a discovery call to talk about how OQSIE can help your team ensure efficiency and effectiveness.

Sources:

1. McKinsey & Company’s “Generative AI in the pharmaceutical industry: Moving from hype to reality”
2. Arnold & Porter’s “AI is Transforming Life Sciences but Raising Risk Concerns, New Benchmark Report Finds”
3. European Pharmaceutical Manufacturer’s “AI: A strategic imperative for pharmaceutical supply chains”
4. Life Sciences Review’s “Global Harmonization And Emerging Trends In Life Sciences Regulation”
5. Deloitte’s “To digitize its supply chain, biopharma may first need to close a workforce skills gap”

The FDA’s Five Areas of Consideration for AI in Drug Manufacturing

September 2024

Artificial Intelligence (AI) has been a topic of conversation in the life sciences industry for years now. While some have made progress adopting this technology, most are beginning to explore the possibilities it offers across the value chain, and just scratching the surface on the opportunities it holds for drug manufacturing.  

As it transforms the manufacturing space, the FDA has been evaluating different use cases and how to regulate it in efforts to help inform the existing regulatory framework. In 2023, the Agency published a discussion paper which dove deeper into the uses and potential risks of AI in drug manufacturing, as part of the Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative.  

In addition to providing some potential applications of AI in pharmaceutical manufacturing, the FDA also presented some areas of consideration they were seeking feedback on. These areas focused on the manufacture of drug products that would be marketed under a New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologics License Application (BLA).  

The FDA’s Artificial Intelligence in Drug Manufacturing paper lists the following five areas of consideration associated with AI:  

1. “Cloud applications may affect oversight of pharmaceutical manufacturing data and records. 

2. The IOT [Internet of Things] may increase the amount of data generated during pharmaceutical manufacturing, affecting existing data management practices. 

3. Applicants may need clarity about whether and how the application of AI in pharmaceutical manufacturing is subject to regulatory oversight. 

4. Applicants may need standards for developing and validating AI models used for process control and to support release testing. 

5. Continuously learning AI systems that adapt to real-time data may challenge regulatory assessment and oversight.” 

All in all, these areas of consideration pointed to some key themes the FDA is evaluating; ensuring data integrity and quality, managing the potential influx of data, identifying which applications will require regulatory oversight, AI model development and validation, and managing expectations for continuous AI learning systems.  

The discussion paper also highlights some potential associated requirements and policies. You can read the FDA’s Artificial Intelligence in Drug Manufacturing discussion paper here.  

Sources:

U.S. FDA’s Center for Drug Evaluation and Research “Artificial Intelligence in Drug Manufacturing” Discussion Paper

FDA Voices: FDA releases papers on AI and Machine Learning in drug development and manufacturing

Top Reasons Life Sciences Companies Receive FDA Citations

June 2024

Navigating FDA regulations and staying on top of compliance is critical to the success of a company and product safety. Despite rigorous efforts to maintain compliance, many companies still encounter FDA citations. Understanding common pitfalls can help your organization stay compliant and avoid these costly issues.  

The FDA’s data has helped us understand where companies are underperforming and highlights an important area life sciences companies struggle to comply with. In Figure 1, we see the top citation over the past 15 years across all FDA program areas is Devices-21 CFR 820.100(a)- Lack of or inadequate procedures.

In the life sciences industry, we see a common problem across the board: proper procedures are either not in place or they are not being followed. Figure 2 shows that most of the top citations for Devices are due to a lack of or inadequate procedures.  

Similarly, Figure 3 demonstrates that the citations for Drugs vary, but problems with procedures remain the top reason for citations.  

As post-pandemic inspections continue, it is vital to ensure the proper procedures are in place and being followed. Without the proper support in place, these areas can quickly turn into an FDA citation and result in massive financial losses and reputational damage that are difficult to bounce back from.  

You can stay on top of regulatory compliance and remediate issues by conducting audits, quality management system gap assessments, and addressing capacity and/or capability gaps with industry-experienced OQSIE consultants.

Want to learn more on how we can help you avoid or resolve FDA citations? Submit a request for more information.  

Source: United States Food and Drug Administration’s Data Dashboard